Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
CEO and Fund Manager, Renaissance Venture Capital Fund
Director, Life Sciences Institute, University of Michigan
President and CEO of the Central Indiana Corporate Partnership
After a 2016 filled with extreme highs and lows, biotech is in for yet another bumpy ride in 2017. Obamacare’s future is uncertain. The 21st Century Cures Act is in place. Changes loom at the FDA, drug pricing remains a flashpoint, and the IPO market continues to sputter. Yet through it all, critical biotech advances are being made. In cancer immunotherapy, drug cocktails may boost the power of existing treatments. For the first time, a CRISPR-Cas9 gene editing product could be tested in a human being–and a gene therapy submitted for approval in the U.S. Patients and their advocates are being incorporated into the drug development and approval process like never before.
What ideas are Boston’s innovators focusing on? What are the most promising startups and big company programs, and how does their leadership plan to move ideas forward amidst the shifting political and healthcare landscape?
Join Xconomy as we bring together a group of Boston biotech’s top entrepreneurs, investors, and leaders to explore these and other topics on the life sciences horizon.
Confirmed speakers include:
Noubar Afeyan, Founder, Senior Managing Partner & CEO, Flagship Pioneering
Katrine Bosley, CEO, Editas Medicine
Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute
Stelios Papadopoulos, Chairman of the Board, Biogen; Co-founder & Chairman of the Board, Exelixis
Richard Pops, Chairman & CEO, Alkermes
Susan Windham-Bannister, P.h.D., President and CEO, Biomedical Growth Strategies; Managing Partner, Biomedical Innovation Advisors
Michael Gilman, CEO & Chairman, Arrakis Therapeutics
Abbie Celniker, Partner, Third Rock Ventures
David Schenkein, CEO, Agios Pharmaceuticals
Ed Kaye, President, CEO & Chief Medical Officer, Sarepta Therapeutics
Tony Coles, Chairman & CEO, Yumanity Therapeutics
Jeremy Levin, CEO, Ovid Therapeutics; former CEO, Teva Pharmaceutical Industries
Peter Saltonstall, President & CEO, National Organization for Rare Disorders
Peter Koutoujian, Sheriff of Middlesex County, former member, Massachusetts House of Representatives
Teresa Lavoie, Partner, Fish & Richardson
Registration & Networking: 12:30 – 1:30 pm
Program: 1:30 – 5:30 pm
Networking Reception: 5:30 – 6:30 pm
Home Stretch: $295
Regular Registration: $375
Startup Special: $195
At the Door: $425
Tickets are transferable but not refundable.
Speakers and program schedule are subject to change.